AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
26-06-19	0.8500 €	-2.30%
26-06-18	0.8700 €	+1.16%
26-06-17	0.8600 €	-2.71%
26-06-16	0.8840 €	-0.90%
26-06-15	0.8920 €	0.00%

Delayed Quote Deutsche Boerse AG

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Deutsche Boerse AG Other stock markets 02:02:12 2026-06-19 am EDT			5-day change	1st Jan Change
0.8500 ^EUR	-2.30%		-4.71%	-37.68%

Jun. 18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
Jun. 18	AB Science Secures New U.S. Patent for Masitinib

Market Cap	68.5M 78.57M 63.44M 59.39M 111M 7.41B 112M 753M 292M 3.65B 295M 289M 12.67B	P/E 2025 *	-	P/E 2026 *	-
Enterprise Value	68.5M 78.57M 63.44M 59.39M 111M 7.41B 112M 753M 292M 3.65B 295M 289M 12.67B	EV / Sales 2025	95.4x	EV / Sales 2026 *	57.1x
Free-Float	67.54%	Yield 2025 *	-	Yield 2026 *	-

Jun. 18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
Jun. 18	AB Science Secures New U.S. Patent for Masitinib
Jun. 17	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
Jun. 10	AB Science presents new data on Masitinib
May. 17	AB Science S.A. announced that it has received $2.989368 million in funding	CI
May. 13	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
May. 03	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
Apr. 29	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
Apr. 29	AB Science announces successful capital increase
Apr. 28	Air Liquide, Nexans, AB Science... stocks to watch today in Paris
Apr. 28	AB Science Reaches Maturity Extension Deal with Lenders	MT
Apr. 27	Vinci, Lumibird, SergeFerrari... stocks to watch tomorrow in Paris
Apr. 27	AB Science announces major agreement with creditors

Jun. 17	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042	GL
Jun. 09	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS	GL
Jun. 02	AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share	GL
May. 26	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of EUR4.00 per share	AQ
May. 25	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share	GL

AB Science Stock Deutsche Boerse AG

Stocks

A8D

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

Jun. 18	Bourse : L'Oréal met le cap sur l'Inde, gros contrat pour Alstom, rumeur sur Edenred
Jun. 18	Star Warsh
Jun. 18	AB Science obtient un nouveau brevet américain pour son masitinib
Jun. 17	Le brevet d’AB Science concernant le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant a été officiellement délivré aux Etats-Unis avec une durée de protection jusqu’en 2042
Jun. 10	Bourse : Airbus veut rebondir sur le SCAF, Legrand se renforce, le marché attend Oracle

1 day	-2.30%
1 week	-4.71%
Current month	-13.00%
1 month	-10.90%
3 months	-29.98%
6 months	-29.64%
Current year	-37.68%

1 week	0.85	0.99
1 month	0.85	0.99
Current year	0.85	1.55
1 year	0.85	1.69
3 years	0.73	4.46
5 years	0.73	15.72
10 years	0.73	20.1

Manager	Title	Age	Since
Alain Moussy CEO	Chief Executive Officer	-	2001-07-10
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Patrick Moussy BRD	Director/Board Member	-	2011-09-19
Cécile de Guillebon BRD	Director/Board Member	64	2021-06-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-2.30%	-4.71%	-	-	78.57M
MERCK & CO., INC.	-1.36%	-4.35%	+44.03%	+3.30%	281B
MERCK KGAA	-0.11%	-0.26%	+20.49%	-14.40%	66.27B
KYOWA KIRIN CO., LTD.	+1.30%	+5.71%	+2.24%	-7.88%	8.24B
HALOZYME THERAPEUTICS, INC.	-0.03%	-1.37%	+29.80%	+98.29%	8.13B
SK BIOPHARMACEUTICALS CO., LTD.	-1.92%	-1.02%	-6.35%	+4.44%	4.45B
YUHAN CORPORATION	-2.69%	-1.42%	-26.97%	+36.12%	3.71B
BETTA PHARMACEUTICALS CO., LTD.	+8.33%	+2.08%	+0.22%	+12.14%	3.42B
SUPERNUS PHARMACEUTICALS, INC.	+1.84%	-0.07%	+37.48%	+32.32%	2.58B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-1.01%	-2.64%	+5.02%	-26.66%	1.92B
Average	+0.21%	-1.51%	+11.77%	+15.30%	42.22B
Weighted average by Cap.	-0.97%	-4.30%	+36.79%	+2.46%

	2025	2026 *
Net sales	1.1M 1.26M 1.02M 954K 1.79M 119M 1.8M 12.09M 4.68M 58.59M 4.74M 4.63M 203M	1.2M 1.38M 1.11M 1.04M 1.95M 130M 1.96M 13.18M 5.11M 63.92M 5.17M 5.06M 222M
Net income	-	-
Net Debt	-	-